AD105

AD105 is a small molecule anti-inflammatory drug candidate developed by Jiangsu Aidi Pharmaceutical, currently in Phase 1/2 clinical trials. It is specifically designed to manage excessive inflammatory responses, such as systemic inflammatory response syndrome (SIRS), that can occur following thrombolytic therapy in conditions like acute ischemic stroke or myocardial infarction. By inhibiting the inflammatory cascade triggered during reperfusion and thrombolysis, AD105 aims to reduce secondary tissue damage and improve clinical outcomes for patients undergoing these procedures. The drug is positioned as a small molecule alternative or adjunct to protein-based protease inhibitors like ulinastatin, targeting the acute inflammatory complications associated with the restoration of blood flow.